By Pushkala Aripaka and Maggie Fick (Reuters) -AstraZeneca shares rose on Thursday after the drugmaker said it could face a ...

AstraZeneca could face a fine of up to $4.5 million in China over suspected unpaid taxes related to the import of two of its ...

AstraZeneca said on Thursday it has received a notice in China over unpaid taxes related to the import of two cancer ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

AstraZeneca Plc reported better-than-expected profit and sales in the fourth quarter and forecast further gains as the UK drugmaker’s blockbuster cancer drugs offset weakened China sales.

AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter 2024. The London-listed company ...

The AstraZeneca PLC ADR AZN advanced 2.86% to $70.94 Wednesday, on what proved to be an all-around favorable trading session ...

AstraZeneca has cancelled a multi-million pound investment in a vaccine plant in Merseyside because the government failed to ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...